QUEST DIAGNOSTICS ($DGX) posted quarterly earnings results for Q1 2026 on Tuesday, April 21st. The company reported earnings of $2.50 per share, beating estimates of $2.37 by $0.13. The company also reported revenue of $2,895,000,000, beating estimates of $2,854,867,373 by $40,132,627.
You can see Quiver Quantitative's $DGX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
QUEST DIAGNOSTICS Insider Trading Activity
QUEST DIAGNOSTICS insiders have traded $DGX stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:
- J. E. DAVIS (CEO and President) has made 0 purchases and 4 sales selling 65,093 shares for an estimated $12,714,959.
- CATHERINE T. DOHERTY (EVP, Regional Businesses) has made 0 purchases and 8 sales selling 33,788 shares for an estimated $6,964,736.
- PATRICK PLEWMAN (SVP for Diagnostic Services) has made 0 purchases and 4 sales selling 9,885 shares for an estimated $2,025,173.
- MARK E DELANEY (SVP & Chief Commercial Officer) sold 7,946 shares for an estimated $1,488,683
- MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 5,515 shares for an estimated $1,136,514.
- KARTHIK KUPPUSAMY (SVP, Clinical Solutions) sold 2,628 shares for an estimated $538,372
- GARY M PFEIFFER sold 1,482 shares for an estimated $270,316
- VICKY B GREGG sold 1,250 shares for an estimated $239,700
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
QUEST DIAGNOSTICS Hedge Fund Activity
We have seen 454 institutional investors add shares of QUEST DIAGNOSTICS stock to their portfolio, and 440 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,759,509 shares (-76.5%) from their portfolio in Q4 2025, for an estimated $478,857,596
- WELLINGTON MANAGEMENT GROUP LLP removed 1,341,737 shares (-93.1%) from their portfolio in Q4 2025, for an estimated $232,831,621
- EDGEPOINT INVESTMENT GROUP INC. added 811,320 shares (+95.5%) to their portfolio in Q4 2025, for an estimated $140,788,359
- PRICE T ROWE ASSOCIATES INC /MD/ removed 708,833 shares (-10.1%) from their portfolio in Q4 2025, for an estimated $123,003,790
- BLACKROCK, INC. removed 542,817 shares (-5.4%) from their portfolio in Q4 2025, for an estimated $94,195,034
- RTW INVESTMENTS, LP removed 500,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $86,765,000
- NEUBERGER BERMAN GROUP LLC removed 474,675 shares (-91.5%) from their portfolio in Q4 2025, for an estimated $82,370,352
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
QUEST DIAGNOSTICS Government Contracts
We have seen $137,249,838 of award payments to $DGX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMY: $8,400,000
- VISN 7 REFERENCE LAB SERVICES: $8,250,000
- REFERENCE LAB TESTING - OPTION 2: $3,375,189
- REFERENCE LAB TESTING - ADD AND EXERCISE OPTION: $2,804,456
- REFERENCE LAB TESTS: $2,748,684
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
QUEST DIAGNOSTICS Congressional Stock Trading
Members of Congress have traded $DGX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DGX stock by members of Congress over the last 6 months:
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 11/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
QUEST DIAGNOSTICS Analyst Ratings
Wall Street analysts have issued reports on $DGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 02/11/2026
To track analyst ratings and price targets for QUEST DIAGNOSTICS, check out Quiver Quantitative's $DGX forecast page.
QUEST DIAGNOSTICS Price Targets
Multiple analysts have issued price targets for $DGX recently. We have seen 8 analysts offer price targets for $DGX in the last 6 months, with a median target of $217.5.
Here are some recent targets:
- Elizabeth Anderson from Evercore ISI Group set a target price of $210.0 on 04/08/2026
- Ann Hynes from Mizuho set a target price of $235.0 on 02/12/2026
- Tycho Peterson from Jefferies set a target price of $220.0 on 02/11/2026
- Stephanie Davis from Barclays set a target price of $225.0 on 02/11/2026
- Kevin Caliendo from UBS set a target price of $210.0 on 02/11/2026
- David Macdonald from Truist Securities set a target price of $220.0 on 02/11/2026
- Patrick Donnelly from Citigroup set a target price of $215.0 on 02/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
